Amgen has launched Amgen Community Oncology Research Collaborators (ACORC) that will work to expand clinical trial access to patients suffering with cancer who are treated outside of academic centres in the US.
According to American Cancer Society , fewer than one in 20 adult cancer patients in the country have taken part in a clinical trial.
The collaboration will see enables Amgen widen its clinical research footprint to over 200 patient care centres in the US.
It will also help community centres to reach over 900,000 new patients annually with investigational drugs.
Amgen chief medical officer and senior vice president of global medical Darryl Sleep said: “About 80 percent of cancer patients across the U.S. are treated outside of an academic institute by a community oncologist, making it critical to expand clinical trials to include patients in the community setting.
“Community oncologists are on the frontline and have significant insights that are instrumental in informing cancer research and clinical trials. By leveraging our collective expertise, Amgen hopes to expand our clinical research footprint to bring innovative trials to community centers as quickly as possible.”
First members that have signed on as the ACORC participants include US Oncology Research and Translational Research In Oncology-US (Trio -US) and its joint work with the University of California, Los Angeles Clinical Research Unit.
The collaboration is expected to provide community oncologists an option to have their patients participate in the clinical studies of investigational agents from Amgen’s pipeline, which includes bispecific T cell engager (BiTE) antibody constructs and new small molecules.
The US Oncology Network president Michael Seiden said: “US Oncology Research allows community-based oncologists to participate in clinical research studies at more than 155 locations across the country.”
TRIO director and UCLA member Jonsson Comprehensive Cancer Center John Glaspy said: “We’re excited to sign on as an ACORC participant to provide our physicians access to studies of new and potentially transformative investigational targets.”